NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
Updated: Feb 5
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.
Sponsor
ClinicalTrials.gov Identifier: NCT05308225
Official Title: A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : April 4, 2022
Click here to see details on ClinicalTrials.gov
Biological: STI-6129
Anti-CD38 Antibody-drug Conjugate STI-6129 (Code C174057)
ADC STI-6129
Anti-CD38 ADC STI-6129
Anti-CD38 Antibody-drug Conjugate STI-6129
Anti-CD38-Duostatin 5.2 ADC STI-6129
CD38-077
LNDS1001
STI 6129
STI-6129
STI6129
Locations
United States, Ohio